Instrument Inactif

Communiqués Entasis Therapeutics Holdings Inc.

Actions

ETTX

US2936141033

Recherche biotechnologique et médicale

Communiqués

11/07/22	Entasis Therapeutics : Termination of a Material Definitive Agreement - Form 8-K	PU
11/07/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
10/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	AQ
09/06/22	Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference	GL
23/05/22	Entasis Therapeutics : Innoviva to Acquire Entasis Therapeutics - Form 8-K	PU
23/05/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23/05/22	ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX	BU
23/05/22	Innoviva to Acquire Entasis Therapeutics	AQ
23/05/22	Innoviva to Acquire Entasis Therapeutics	GL
18/05/22	Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference	AQ
17/05/22	Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference	GL
28/04/22	Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update	AQ
27/04/22	ENTASIS THERAPEUTICS HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
27/04/22	Entasis Therapeutics : Announces First Quarter 2022 Financial Results and Provides Business Update - Form 8-K	PU
27/04/22	Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update	GL
26/04/22	Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference	GL
18/04/22	Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference	AQ
03/03/22	ENTASIS THERAPEUTICS HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
03/03/22	Entasis Therapeutics : Announces Year End 2021 Financial Results and Provides Business Update - Form 8-K	PU
03/03/22	Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update	GL
03/03/22	Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update	GL
25/02/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)	AQ
18/02/22	ENTASIS THERAPEUTICS HOLDINGS INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
02/02/22	Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.	GL
02/02/22	Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.	GL